Proxi MaZiQ array Target Discovery Platform: cell-free identification of drug-interacting proteins using Drug~AirID2C and recombinant human protein arrays
Abstract
Most small-molecule drugs exert their biological effects by binding to proteins, making unbiased target identification essential for evaluating drug specificity and potential off-target effects. Herein, we developed the Proxi MaZiQ array Target Discovery Platform, a cell-free drug-protein interaction detection system that combines recombinant human protein arrays with Drug~AirID ² C, a proximity biotinylation enzyme chemically conjugated to small-molecule compounds. AirID ² C was engineered from AirID by replacing surface-exposed lysine residues with arginine residues while retaining catalytically important lysines and introducing an N-terminal 5K3D tag (KKKDKKDD) for controlled drug conjugation. Drug~AirID ² C molecules prepared using NHS ester chemistry or click chemistry selectively biotinylated known drug-binding proteins, including cereblon for thalidomide and pomalidomide, BET family proteins for JQ1, and HSP90 for geldanamycin, both in solution and on recombinant protein arrays. Biotinylated proteins were detected using AlphaScreen assays and horseradish peroxidase-based array detection. Application of AP-C5~AirID ² C to a kinase- and phosphatase-focused protein array identified candidate AP-C5-interacting proteins, including MINK1, whose kinase activity was inhibited by AP-C5. These results demonstrate that the Proxi MaZiQ array Target Discovery Platform enables biochemical identification of candidate drug-interacting proteins and provides a useful approach for target identification and target-profile analysis of small-molecule compounds in a defined in vitro setting.
Related
- Identification of Novel Interacting Proteins of FUZ and GPR161
- Sti1 requires its Hsp70-interacting regions to deposit misfolded proteins at the nucleus-vacuole junction
- Recombinant SIRT1 expression and SIRT1 METTL3 interaction analysis with computational identification of phytochemical SIRT1 activators and inhibitors
- Sequence-Engineered Recombinant Human Collagen as a Biomacromolecular Platform for Guided Bone Regeneration Membranes
- Identification and characterization of two transmembrane proteins required for virulence of Ustilago maydis
BibTeX
@article{sugiyama2026proxi,
title = {{Proxi MaZiQ array Target Discovery Platform: cell-free identification of drug-interacting proteins using Drug~AirID2C and recombinant human protein arrays}},
author = {Shusei Sugiyama and Miwako Denda and Fumiko Tanabe and Naomi Terawaki and Chikako Takahashi and Shin-ichi Terawaki and Kohdai Yamada and Aki Kohyama and Hiroyuki Yamakoshi and Yoshiharu Iwabuchi and Ryo Morishita and Tatsuya Sawasaki},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-74569-2},
url = {https://www.nature.com/articles/s41598-026-74569-2},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Proxi MaZiQ array Target Discovery Platform: cell-free identification of drug-interacting proteins using Drug~AirID2C and recombinant human protein arrays
AU - Shusei Sugiyama
AU - Miwako Denda
AU - Fumiko Tanabe
AU - Naomi Terawaki
AU - Chikako Takahashi
AU - Shin-ichi Terawaki
AU - Kohdai Yamada
AU - Aki Kohyama
AU - Hiroyuki Yamakoshi
AU - Yoshiharu Iwabuchi
AU - Ryo Morishita
AU - Tatsuya Sawasaki
PY - 2026
DA - 2026/10/09
JO - Scientific Reports
DO - 10.1038/s41598-026-74569-2
UR - https://www.nature.com/articles/s41598-026-74569-2
AB - Most small-molecule drugs exert their biological effects by binding to proteins, making unbiased target identification essential for evaluating drug specificity and potential off-target effects. Herein, we developed the Proxi MaZiQ array Target Discovery Platform, a cell-free drug-protein interaction detection system that combines recombinant human protein arrays with Drug~AirID ² C, a proximity biotinylation enzyme chemically conjugated to small-molecule compounds. AirID ² C was engineered from AirID by replacing surface-exposed lysine residues with arginine residues while retaining catalytically important lysines and introducing an N-terminal 5K3D tag (KKKDKKDD) for controlled drug conjugation. Drug~AirID ² C molecules prepared using NHS ester chemistry or click chemistry selectively biotinylated known drug-binding proteins, including cereblon for thalidomide and pomalidomide, BET family proteins for JQ1, and HSP90 for geldanamycin, both in solution and on recombinant protein arrays. Biotinylated proteins were detected using AlphaScreen assays and horseradish peroxidase-based array detection. Application of AP-C5~AirID ² C to a kinase- and phosphatase-focused protein array identified candidate AP-C5-interacting proteins, including MINK1, whose kinase activity was inhibited by AP-C5. These results demonstrate that the Proxi MaZiQ array Target Discovery Platform enables biochemical identification of candidate drug-interacting proteins and provides a useful approach for target identification and target-profile analysis of small-molecule compounds in a defined in vitro setting.
SN - 2045-2322
ER -